{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:59:39Z","timestamp":1781143179708,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010613","name":"Taipei Medical University Hospital","doi-asserted-by":"publisher","award":["110TMU-TMUH-01-3"],"award-info":[{"award-number":["110TMU-TMUH-01-3"]}],"id":[{"id":"10.13039\/501100010613","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 114-2320-B-038-034-MY3"],"award-info":[{"award-number":["NSTC 114-2320-B-038-034-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 108-2320-B-038-056, NSTC 109-2320-B-038-029, NSTC 114-2320-B-038-037"],"award-info":[{"award-number":["NSTC 108-2320-B-038-056, NSTC 109-2320-B-038-029, NSTC 114-2320-B-038-037"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Direct"],"DOI":"10.1186\/s13062-026-00812-5","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T09:37:15Z","timestamp":1777282635000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A cyclin D1\u2013CDK4\/6\u2013E2F dependency represents an acquired vulnerability in cisplatin-resistant bladder cancer"],"prefix":"10.1186","volume":"21","author":[{"given":"Tsung-Han","family":"Hsieh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Pin","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hsu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Jyun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Chuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Han","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"3","key":"812_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"812_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"7679","key":"812_CR3","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1038\/551S34a","volume":"551","author":"C Berdik","year":"2017","unstructured":"Berdik C. Unlocking bladder cancer. Nature. 2017;551(7679):S34\u20135.","journal-title":"Nature"},{"issue":"4","key":"812_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nrclinonc.2016.188","volume":"14","author":"SA Funt","year":"2017","unstructured":"Funt SA, Rosenberg JE. Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. Nat Rev Clin Oncol. 2017;14(4):221\u201334.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"812_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/CCO.0000000000000064","volume":"26","author":"M Ghosh","year":"2014","unstructured":"Ghosh M, Brancato SJ, Agarwal PK, Apolo AB. Targeted therapies in urothelial carcinoma. Curr Opin Oncol. 2014;26(3):305\u201320.","journal-title":"Curr Opin Oncol"},{"key":"812_CR6","doi-asserted-by":"publisher","first-page":"5682078","DOI":"10.1155\/2018\/5682078","volume":"2018","author":"N Bukhari","year":"2018","unstructured":"Bukhari N, Al-Shamsi HO, Azam F. Update on the Treatment of Metastatic Urothelial Carcinoma. ScientificWorldJournal. 2018;2018:5682078.","journal-title":"ScientificWorldJournal"},{"issue":"9","key":"812_CR7","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.6004\/jnccn.2018.0072","volume":"16","author":"TW Flaig","year":"2018","unstructured":"Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018;16(9):1041\u201353.","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"812_CR8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1078-0432.CCR-15-1135","volume":"22","author":"A Ghasemzadeh","year":"2016","unstructured":"Ghasemzadeh A, Bivalacqua TJ, Hahn NM, Drake CG. New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. Clin Cancer Res. 2016;22(4):793\u2013801.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"812_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1358\/dot.2019.55.8.3010573","volume":"55","author":"KS Hanna","year":"2019","unstructured":"Hanna KS. Erdafitinib to treat urothelial carcinoma. Drugs Today (Barc). 2019;55(8):495\u2013501.","journal-title":"Drugs Today (Barc)"},{"issue":"2","key":"812_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","volume":"66","author":"RS Svatek","year":"2014","unstructured":"Svatek RS, Hollenbeck BK, Holmang S, Lee R, Kim SP, Stenzl A, et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol. 2014;66(2):253\u201362.","journal-title":"Eur Urol"},{"key":"812_CR11","doi-asserted-by":"crossref","unstructured":"Schardt J, Roth B, Seiler R. Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when? World J Urol. 2018.","DOI":"10.1007\/s00345-018-2544-8"},{"issue":"15","key":"812_CR12","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869\u201383.","journal-title":"Oncogene"},{"issue":"2","key":"812_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1586\/era.11.201","volume":"12","author":"RM Drayton","year":"2012","unstructured":"Drayton RM, Catto JW. Molecular mechanisms of cisplatin resistance in bladder cancer. Expert Rev Anticancer Ther. 2012;12(2):271\u201381.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"812_CR14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"2","key":"812_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3233\/BLC-170105","volume":"3","author":"Q Pan","year":"2017","unstructured":"Pan Q, Sathe A, Black PC, Goebell PJ, Kamat AM, Schmitz-Draeger B, et al. CDK4\/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer. Bladder Cancer. 2017;3(2):79\u201388.","journal-title":"Bladder Cancer"},{"issue":"3","key":"812_CR16","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.juro.2015.08.082","volume":"195","author":"A Sathe","year":"2016","unstructured":"Sathe A, Koshy N, Schmid SC, Thalgott M, Schwarzenbock SM, Krause BJ, et al. CDK4\/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1. J Urol. 2016;195(3):771\u20139.","journal-title":"J Urol"},{"issue":"1","key":"812_CR17","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1158\/1078-0432.CCR-18-0685","volume":"25","author":"C Rubio","year":"2019","unstructured":"Rubio C, Martinez-Fernandez M, Segovia C, Lodewijk I, Suarez-Cabrera C, Segrelles C, et al. CDK4\/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status. Clin Cancer Res. 2019;25(1):390\u2013402.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"812_CR18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","volume":"13","author":"B O\u2019Leary","year":"2016","unstructured":"O\u2019Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4\/6 inhibitors. Nat Rev Clin Oncol. 2016;13(7):417\u201330.","journal-title":"Nat Rev Clin Oncol"},{"key":"812_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","volume":"139","author":"R Roskoski","year":"2019","unstructured":"Roskoski R. Jr. Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs. Pharmacol Res. 2019;139:471\u201388.","journal-title":"Pharmacol Res"},{"issue":"16","key":"812_CR20","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.7150\/thno.25130","volume":"8","author":"A Yeon","year":"2018","unstructured":"Yeon A, You S, Kim M, Gupta A, Park MH, Weisenberger DJ, et al. Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism. Theranostics. 2018;8(16):4520\u201334.","journal-title":"Theranostics"},{"key":"812_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2018.08.014","volume":"437","author":"JH Jung","year":"2018","unstructured":"Jung JH, You S, Oh JW, Yoon J, Yeon A, Shahid M, et al. Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target. Cancer Lett. 2018;437:1\u201312.","journal-title":"Cancer Lett"},{"issue":"53","key":"812_CR22","doi-asserted-by":"publisher","first-page":"91199","DOI":"10.18632\/oncotarget.20043","volume":"8","author":"CR Silvers","year":"2017","unstructured":"Silvers CR, Miyamoto H, Messing EM, Netto GJ, Lee YF. Characterization of urinary extracellular vesicle proteins in muscle-invasive bladder cancer. Oncotarget. 2017;8(53):91199\u2013208.","journal-title":"Oncotarget"},{"issue":"2","key":"812_CR23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.eururo.2016.02.046","volume":"70","author":"K Junker","year":"2016","unstructured":"Junker K, Heinzelmann J, Beckham C, Ochiya T, Jenster G. Extracellular Vesicles and Their Role in Urologic Malignancies. Eur Urol. 2016;70(2):323\u201331.","journal-title":"Eur Urol"},{"issue":"5","key":"812_CR24","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1158\/1078-0432.CCR-17-2066","volume":"24","author":"CH Chen","year":"2018","unstructured":"Chen CH, Changou CA, Hsieh TH, Lee YC, Chu CY, Hsu KC, et al. Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer. Clin Cancer Res. 2018;24(5):1176\u201389.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"812_CR25","doi-asserted-by":"publisher","first-page":"8798","DOI":"10.1021\/jf1020158","volume":"58","author":"CY Huang","year":"2010","unstructured":"Huang CY, Chen JY, Wu JE, Pu YS, Liu GY, Pan MH, et al. Ling-Zhi polysaccharides potentiate cytotoxic effects of anticancer drugs against drug-resistant urothelial carcinoma cells. J Agric Food Chem. 2010;58(15):8798\u2013805.","journal-title":"J Agric Food Chem"},{"issue":"1","key":"812_CR26","doi-asserted-by":"publisher","first-page":"20922","DOI":"10.1038\/s41598-025-06543-3","volume":"15","author":"TH Hsieh","year":"2025","unstructured":"Hsieh TH, Kuo HP, Chen MC, Lin YC, Lin BJ, Hsu KC, et al. Hinokiflavone is a novel CK2 inhibitor promoting apoptosis and synergizing with chemotherapeutic agents in cisplatin resistant bladder cancer cells. Sci Rep. 2025;15(1):20922.","journal-title":"Sci Rep"},{"issue":"12","key":"812_CR27","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41419-024-07298-x","volume":"15","author":"CC Tu","year":"2024","unstructured":"Tu CC, Hsieh TH, Chu CY, Lin YC, Lin BJ, Chen CH. Targeting PPARgamma via SIAH1\/2-mediated ubiquitin-proteasomal degradation as a new therapeutic approach in luminal-type bladder cancer. Cell Death Dis. 2024;15(12):908.","journal-title":"Cell Death Dis"},{"key":"812_CR28","doi-asserted-by":"crossref","unstructured":"Chen MC, Lin YC, Liao YH, Liou JP, Chen CH. MPT0G612, a novel HDAC6 inhibitor, induces apoptosis and suppresses IFN-gamma-induced programmed death-ligand 1 in human colorectal carcinoma cells. Cancers (Basel). 2019;11(10).","DOI":"10.3390\/cancers11101617"},{"issue":"18","key":"812_CR29","doi-asserted-by":"publisher","first-page":"26374","DOI":"10.18632\/oncotarget.8380","volume":"7","author":"CH Chen","year":"2016","unstructured":"Chen CH, Liu YM, Pan SL, Liu YR, Liou JP, Yen Y. Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivo. Oncotarget. 2016;7(18):26374\u201387.","journal-title":"Oncotarget"},{"issue":"2","key":"812_CR30","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.18632\/oncotarget.23509","volume":"9","author":"ML Liang","year":"2018","unstructured":"Liang ML, Hsieh TH, Liu YR, Chen YW, Lee YY, Chang FC, et al. Significance of cyclin D1 overexpression in progression and radio-resistance of pediatric ependymomas. Oncotarget. 2018;9(2):2527\u201342.","journal-title":"Oncotarget"},{"issue":"3","key":"812_CR31","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017;171(3):540\u201356. e25.","journal-title":"Cell"},{"key":"812_CR32","first-page":"49","volume":"8","author":"M Cuprych-Belter","year":"2025","unstructured":"Cuprych-Belter M, Lupicka-Slowik A, Anisiewicz A, Michaelis M, Cinatl J Jr., Psurski M. Distinct adaptive strategies to cisplatin, vinblastine and gemcitabine in a panel of chemoresistant bladder cancer cell lines. Cancer Drug Resist. 2025;8:49.","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"812_CR33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.canlet.2012.02.010","volume":"322","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Wang Z, Yu J, Shi J, Wang C, Fu W, et al. Cancer stem-like cells contribute to cisplatin resistance and progression in bladder cancer. Cancer Lett. 2012;322(1):70\u20137.","journal-title":"Cancer Lett"},{"issue":"4","key":"812_CR34","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1002\/jcp.26916","volume":"234","author":"N Aghaalikhani","year":"2019","unstructured":"Aghaalikhani N, Rashtchizadeh N, Shadpour P, Allameh A, Mahmoodi M. Cancer stem cells as a therapeutic target in bladder cancer. J Cell Physiol. 2019;234(4):3197\u2013206.","journal-title":"J Cell Physiol"},{"issue":"3","key":"812_CR35","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.bbagrm.2014.11.008","volume":"1849","author":"CJ Hu","year":"2015","unstructured":"Hu CJ, Wang B, Tang B, Chen BJ, Xiao YF, Qin Y, et al. The FOXM1-induced resistance to oxaliplatin is partially mediated by its novel target gene Mcl-1 in gastric cancer cells. Biochim Biophys Acta. 2015;1849(3):290\u20139.","journal-title":"Biochim Biophys Acta"},{"issue":"34","key":"812_CR36","doi-asserted-by":"publisher","first-page":"29075","DOI":"10.1074\/jbc.M112.365494","volume":"287","author":"JL Dean","year":"2012","unstructured":"Dean JL, McClendon AK, Knudsen ES. Modification of the DNA damage response by therapeutic CDK4\/6 inhibition. J Biol Chem. 2012;287(34):29075\u201387.","journal-title":"J Biol Chem"},{"issue":"4","key":"812_CR37","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nrurol.2017.16","volume":"14","author":"AM Kamat","year":"2017","unstructured":"Kamat AM, Colombel M, Sundi D, Lamm D, Boehle A, Brausi M, et al. BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nat Rev Urol. 2017;14(4):244\u201355.","journal-title":"Nat Rev Urol"},{"key":"812_CR38","doi-asserted-by":"crossref","unstructured":"Holzbeierlein J, Bixler BR, Buckley DI, Chang SS, Holmes RS, James AC, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; Amended 2020, 2024). J Urol. 2024;212(1):3\u201310.","DOI":"10.1097\/JU.0000000000003981"},{"issue":"24","key":"812_CR39","doi-asserted-by":"publisher","first-page":"21944","DOI":"10.1002\/cam4.6768","volume":"12","author":"ZA Hannouneh","year":"2023","unstructured":"Hannouneh ZA, Hijazi A, Alsaleem AA, Hami S, Kheyrbek N, Tanous F, et al. Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer. Cancer Med. 2023;12(24):21944\u201368.","journal-title":"Cancer Med"},{"issue":"10","key":"812_CR40","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.urolonc.2021.05.015","volume":"39","author":"ND Shore","year":"2021","unstructured":"Shore ND, Palou Redorta J, Robert G, Hutson TE, Cesari R, Hariharan S, et al. Non-muscle-invasive bladder cancer: An overview of potential new treatment options. Urol Oncol. 2021;39(10):642\u201363.","journal-title":"Urol Oncol"},{"key":"812_CR41","doi-asserted-by":"crossref","unstructured":"Deininger S, Torzsok P, Mitterberger M, Pallauf M, Oswald D, Deininger C, et al. From interferon to checkpoint inhibition therapy-a systematic review of new immune-modulating agents in bacillus calmette-guerin (BCG) refractory non-muscle-invasive bladder cancer (NMIBC). Cancers (Basel). 2022;14(3).","DOI":"10.3390\/cancers14030694"},{"issue":"7668","key":"812_CR42","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, et al. CDK4\/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471\u20135.","journal-title":"Nature"},{"issue":"10","key":"812_CR43","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s12032-025-02996-8","volume":"42","author":"SA Hussein","year":"2025","unstructured":"Hussein SA, Saadawy AH, Badr E, Abdollah MRA, Wael N, Allam RM, et al. The landscape of cyclin-dependent kinase 4\/6 inhibitors in solid malignancies: emphasis on immunotherapy combinatorial strategies. Med Oncol. 2025;42(10):447.","journal-title":"Med Oncol"},{"issue":"2","key":"812_CR44","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","volume":"8","author":"J Deng","year":"2018","unstructured":"Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, et al. CDK4\/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov. 2018;8(2):216\u201333.","journal-title":"Cancer Discov"},{"issue":"1","key":"812_CR45","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/s41467-023-36892-4","volume":"14","author":"X Bai","year":"2023","unstructured":"Bai X, Guo ZQ, Zhang YP, Fan ZZ, Liu LJ, Liu L, et al. CDK4\/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy. Nat Commun. 2023;14(1):1247.","journal-title":"Nat Commun"}],"container-title":["Biology Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13062-026-00812-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00812-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00812-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:26:51Z","timestamp":1781141211000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13062-026-00812-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["812"],"URL":"https:\/\/doi.org\/10.1186\/s13062-026-00812-5","relation":{},"ISSN":["1745-6150"],"issn-type":[{"value":"1745-6150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}